Study of HuCNS-SC Cells in Patients With Infantile or Late Infantile Neuronal Ceroid Lipofuscinosis (NCL)
Neuronal Ceroid Lipofuscinosis
About this trial
This is an interventional treatment trial for Neuronal Ceroid Lipofuscinosis focused on measuring NCL, INCL, LINCL, Batten disease, Infantile Neuronal Ceroid Lipofuscinosis (INCL), Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL)
Eligibility Criteria
Inclusion Criteria: Patients MAY be eligible to participate in this research study if they: Are age 18 months to 12 years old Have a clinical diagnosis of infantile neuronal ceroid lipofuscinosis (INCL) or late infantile neuronal ceroid lipofuscinosis (LINCL) Have a mutation of the CLN1 or CLN2 gene Have severe cognitive, communication, behavior and language impairment Exclusion Criteria: Patients may not be eligible to participate in this research study if they: Have cognitive, communication, behavior and language function less than that of a 1 year old Have previously received an organ, tissue or bone marrow transplantation Have previously participated in any gene or cell therapy study Have infection with hepatitis virus, Cytomegalovirus, Epstein Barr Virus, or Human Immunodeficiency Virus (HIV) Have a current or prior cancer Have a bleeding disorder Are unable to have an MRI scan
Sites / Locations
- Oregon Health and Science University
Arms of the Study
Arm 1
Experimental
HuCNS-SC
human central nervous system stem cells